# Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

> **NCT00515892** · PHASE1 · UNKNOWN · sponsor: **Cambridge Antibody Technology** · enrollment: 50 (estimated)

## Conditions studied

- Leukemia
- Non-Hodgkin's Lymphoma
- NHL

## Interventions

- **DRUG:** Immunotoxin therapy
- **DRUG:** CAT-8015 Immunotoxin
- **PROCEDURE:** Biological therapy
- **PROCEDURE:** Antibody Therapy
- **PROCEDURE:** Monoclonal Antibody Therapy

## Key facts

- **NCT ID:** NCT00515892
- **Lead sponsor:** Cambridge Antibody Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2007-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515892, "Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00515892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*